Flush with the success of its mRNA Covid-19 vaccine, BioNTech is now gearing up for one of the biggest challenges in vaccine development — which comes without potential profit.
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.
Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.
In particular, he emphasized his belief in tau as a potential target — even though gosuranemab, the lead anti-tau antibody, had just failed a Phase II study.
ENDPOINTS NEWSby John Carroll & team — all the news at 11:30am ET
EARLY EDITIONby Arsalan Arif — news and links at 7:15am ET
ENDPOINTS MANUFACTURINGWeekly biopharma manufacturing report, Thursdays at 2pm ET
UK
Australia
France
Germany
Russia
India
Canada